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Background

Results

Discussion

• Headache is a frequent complaint in the pediatric emergency
department (ED) with 40% - 65% being a primary headache disorder.
• Patients frequently present after failing home therapy.
• Common first line treatments for these intractable headaches are
dopamine receptor antagonists.
• Previous studies have shown prochlorperazine and metoclopramide to
be effective without any serious side effects, but it is unclear which
medication is superior in the acute treatment of intractable headache in
the pediatric ED.

Demographics

• There was no statistically significant difference in ED LOS (6.904 vs 6.663
hours, P=0.7) or mean pain score (5.00 vs 5.01, P=0.9).

Age

Sex

Race

Mean

Total
(n=310)

Metoclopramide
(n=208) | 67.10%

Prochlorperazine
(n=102) | 32.90%

16.8

17.4

15.6

Median

17.0

18.0

16.0

Female

221 (71%)

145 (70%)

76 (75%)

Male

89 (29%)

63 (30%)

26 (25%)

Black

51 (16%)

39 (19%)

12 (12%)

Other

58 (19%)

39 (19%)

19 (19%)

White

201 (65%)

130 (62%)

71 (69%)

Objective
1. To determine if intravenous (IV) prochlorperazine is superior to IV
metoclopramide in the treatment of intractable headache in the
pediatric emergency department.
2. To evaluate the treatment failure rate between prochlorperazine and
metoclopramide.

Methods
This study is a retrospective cohort comparing IV prochlorperazine 0.15mg/kg (max 10mg)
versus IV metoclopramide 0.25mg/kg (max dose 20mg) for the treatment of intractable
headache in the pediatric ED.
Patient Selection

Inclusion Criteria:

Exclusion Criteria:

Ages: 5-21 years

At least 1 dose of
ibuprofen at home
without relief

Any contraindications
to the medications
Altered mental status
Abnormal vital signs
Focal neurological
deficit with clinical
suspicion of meningitis

Study dates: 1/20196/2021
Complaint of isolated
severe headache

Metoclopramide
(n=208) | 67.10%

• This study was retrospective, and hence the information available is
limited by what data was collected. For example, this study originally
wanted to compare baseline pain values on the VAS with those at 1, 2,
and 24 hours or at discharge after receiving the dopamine antagonist.
Additionally, we wanted to study the rates of admission and readmission
within 48 hours for the same complaint.
• Future studies comparing metoclopramide and prochlorperazine should
be prospective so that these variables can be controlled.

Outcomes
Total

• The prochlorperazine group had a statistically significant higher chance of
receiving the rescue medications ketorolac (P=0.002) or diphenhydramine
(P=0.03).

Prochlorperazine
(n=102) | 32.90%

P-value

ED LOS (hours)
Mean
Median
Pain Score after
Medication
Mean
Median

6.825
5.233

6.904
5.292

6.663
5.067

N = 224

N = 144

N = 80

5.004
5.00

5.000
5.000

5.013
5.000

0.8583

Readmission

20 (6.45%)

14 (6.73%)

6 (5.88%)

0.7751

Rescue Medication
Ketorolac

181 (58.93%)

109 (52.40%)

72 (70.59%)

0.0023

Rescue Medication
Diphenhydramine

235 (75.81%)

150 (72.12%)

85 (83.33%)

0.0302

0.6980

• This study further supported previous data suggesting no significant
differences in treatment outcomes between metoclopramide and
prochlorperazine. Performing a cost analysis on these agents may be able
to distinguish if one of these medications is better for the patients.

Conclusion
• There was no difference in pain scores or ED LOS between
prochlorperazine and metoclopramide.
• Patients receiving prochlorperazine had a higher chance of requiring a
rescue medication.
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● Objective 1: Measured using patients’ reported pain score on the visual analogue scale
(VAS) and ED length-of-stay (LOS).
● Objective 2: Treatment failure rate was measured by the need for a rescue medication..
● Descriptive analysis of the patient’s characteristics compares age, sex, and race.
● Categorical variables are described as proportions with 95% confidence intervals (CI).
● Continuous variables: described as means and 95% CI; p-value of ≤ 0.05 is considered
statistically significant
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